当前位置: 首页? 政策法规? 国外法规? (EU) 2015/402:拒绝批准某些用于食品不涉及降低疾病风险和儿童成长健康有关的声?refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health)

(EU) 2015/402:拒绝批准某些用于食品不涉及降低疾病风险和儿童成长健康有关的声?refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health)

扫描二维 分享好友和朋友圈
放大字体缩小字体2015-03-13 04:25:19 来源9a href="http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2015.067.01.0001.01.ENG" target="_blank" rel="nofollow">EUROPE浏览次数9span id="hits">3353
核心提示?015??2日,欧盟发布委员会条?EU) 2015/402,拒绝批?种食品健康声称,分别?)Dictyolone?中的粉团扇藻提取物可通过补钙和蛋白质骨骼的生理修复改善骨密度,特别有助于改善正常健康人群衰老过程造成的骨质疏松?)胞二磷胆碱(CDP-胆碱或胞磷胆碱):CDP-胆碱口服液中的胆碱有助于维持眼神经结构的正常功能?)洛斯巴赫矿泉水有助于集中注意力、/div>
发布单位
EUROPEAN COMMISSION
EUROPEAN COMMISSION
发布文号 (EU) 2015/402
发布日期 2015-03-12 生效日期 暂无
有效性状?/th> 废止日期 暂无
备注 2015??2日,欧盟发布委员会条?EU) 2015/402,拒绝批?种食品健康声称,分别?)Dictyolone?中的粉团扇藻提取物可通过补钙和蛋白质骨骼的生理修复改善骨密度,特别有助于改善正常健康人群衰老过程造成的骨质疏松?)胞二磷胆碱(CDP-胆碱或胞磷胆碱):CDP-胆碱口服液中的胆碱有助于维持眼神经结构的正常功能?)洛斯巴赫矿泉水有助于集中注意力、/td>

  COMMISSION REGULATION (EU) 2015/402

  of 11 March 2015

  refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health

  (Text with EEA relevance)

  THE EUROPEAN COMMISSION,

  Having regard to the Treaty on the Functioning of the European Union,

  Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods (1), and in particular Article 18(5) thereof,

  Whereas:

  (1)

  Pursuant to Regulation (EC) No 1924/2006 health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.

  (2)

  Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State. The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as the Authority, for a scientific assessment, as well as to the Commission and the Member States for information.

  (3)

  The Authority is to deliver an opinion on the health claim concerned.

  (4)

  The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.

  (5)

  Following an application from ICP Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Padina pavonica-extract in Dictyolone? and increase in bone mineral density (Question No EFSA-Q-2013-00249) (2). The claim proposed by the applicant was worded as follows: improves bone density through calcitrophic effects and through the physiological restoration of proteinous bone, particular in bone loss brought about by the aging process on normal healthy persons.

  (6)

  On 10 January 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Padina pavonica-extract in Dictyolone? and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (7)

  Following an application from Omikron Italia S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of cytidine 5-diphosphocholine (CDP-choline or citicoline) and maintenance of normal vision (Question No EFSA-Q-2013-00757) (3). The claim proposed by the applicant was worded as follows: CDP-choline in oral solution as source of choline contributes to the maintenance of normal function of the ophthalmic nervous structures.

  (8)

  On 21 February 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of cytidine 5-diphosphocholine and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (9)

  Following an application from Hassia Mineralquellen GmbH & Co KG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Rosbacher drive? and increased attention (Question No EFSA-Q-2013-00444) (4). The claim proposed by the applicant was, inter alia, worded as follows: helps/supports/maintains concentration.

  (10)

  On 24 February 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Rosbacher drive? and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (11)

  The comments from the applicants and the members of the public received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.

  (12)

  The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

  HAS ADOPTED THIS REGULATION:

  Article 1

  The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.

  Article 2

  This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

  This Regulation shall be binding in its entirety and directly applicable in all Member States.

  Done at Brussels, 11 March 2015.

  For the Commission

  The President

  Jean-Claude JUNCKER

ANNEX
Rejected health claims
Application Relevant provisions of Regulation (EC) No 1924/2006
Nutrient, substance, food or food category
Claim
EFSA opinion reference
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Padina pavonica-extract in Dictyolone?
Improves bone density through calcitrophic effects and through the physiological restoration of proteinous bone, particular in bone loss brought about by the aging process on normal healthy persons
Q-2013-00249
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Cytidine 5-diphosphocholine (CDP-choline or citicoline)
CDP-choline in oral solution as source of choline contributes to the maintenance of normal function of the ophthalmic nervous structures
Q-2013-00757
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Rosbacher drive?
Helps/supports/maintains concentration
Q-2013-00444
食品伙伴网提供标准法规解读、舆情监控、合规咨询、申报注册等服务、br/>电询?535-2129301
QQ?891238009
食品标法? border=
实时把握 食品标法动?/span>
请扫码关?span class="color2">食品标法圇/span>

声明9/p>

凡本网所有原?编译文章及图片、图表的版权均属食品伙伴网所有,如要转载,需注明“信息来源:食品伙伴网”、br> 凡本网注明“信息来源:XXX(非食品伙伴网)”的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责、br> 邮箱:law#www.sqrdapp.com(发邮件时请?换成@ QQ?39307733

[ 政策法规搜索] [ 加入收藏] [ 告诉好友] [ 打印本文] [ 关闭窗口]

Baidu
map